Faruqi and Faruqui, LLP Logo
Share this page

Depomed, Inc. (DEPO)

NASDAQ:DEPO

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Depomed, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Depomed, Inc. (“Depomed” or the “Company”) (NASDAQ:DEPO) of the October 17, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Depomed stock or options between February 26, 2015 and August 7, 2017 and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

The lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all those who purchased Depomed securities between February 26, 2015 and August 7, 2017 (the “Class Period”).  The case, Huang v. Depomed, Inc. et al, No. 3:17-cv-04830 was filed on August 21, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Depomed engaged in questionable practices in connection with the sales and marketing of the Company’s opioid products; (ii) when the aforementioned conduct became known, it would likely subject the Company to heightened legal and regulatory scrutiny; and (iii) as a result, Depomed’s public statements were materially false and misleading.

Specifically, after market on August 7, 2017, Depomed disclosed that the Company “recently received a request for information from the ranking minority member of the United States Senate Committee on Homeland Security and Governmental Affairs related to the promotion of opioids.”  In addition, the Company had also received “subpoenas related to opioid sales and marketing from the Office of the Attorney General of Maryland and the United States Department of Justice.”

On this news, Depomed’s share price fell from $9.23 per share on August 7, 2017 to a closing price of $6.15 on August 8, 2017 —a $3.08 or a 33.37% drop.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Depomed, Inc. (DEPO)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 08/22/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.